ICH E6(R3) Explained: What Clinical Operations Leaders Need to Do Now
Most clinical teams have already read the summary of ICH E6(R3). Fewer have sat down and asked what it changes on a Monday morning. The revised Good Clinical Practice guideline asks sponsors to think harder about what matters most to participant safety and data reliability, and to spend their effort accordingly.
What is ICH E6(R3)?
ICH E6(R3) is the third revision of the International Council for Harmonisation's Good Clinical Practice guideline. It sets the expectations for how clinical trials are designed, conducted, recorded and reported. Compared with earlier versions, it puts more weight on quality by design, proportionate risk management and clear accountability. It is also written to accommodate a wider range of trial designs and data sources.
The practical message is simple. Not every activity needs the same level of control. Teams should identify the factors that are critical to quality and direct their attention there.
Where operations teams will feel it most
Proportionate oversight
Many sponsors still apply broad, uniform monitoring and documentation habits because they are familiar. E6(R3) asks teams to justify their approach based on risk to participants and to the reliability of results. That means defining critical data and processes early, before the protocol is final, and agreeing on how they will be protected.
Data governance and technology
Trials now draw on electronic systems, wearables, remote assessments and outside data sources. The guideline expects sponsors and investigators to understand where data comes from, who can change it and how it is kept secure. Teams that treat data governance as an IT matter often find the gaps late.
Sponsor, site and vendor responsibilities
Sponsors remain accountable even when work is outsourced. Oversight of CROs and service providers has to be documented and proportionate, not assumed. Sites, in turn, need clarity about what is expected of them and why, which is much easier when the protocol has been designed with their workload in mind.
Common implementation gaps
Several patterns appear again and again:
-
Standard operating procedures updated on paper, but not reflected in daily practice
-
Critical-to-quality factors discussed once at kickoff and never revisited
-
Vendor oversight plans that list activities without defining what good looks like
-
Training that explains the guideline but does not change how decisions are made
A short readiness check
Ask your team these five questions:
-
Can we name the critical-to-quality factors for each active study?
-
Does our monitoring approach match the actual risks, or only our past habits?
-
Do we know who owns each data source, and how it is controlled?
-
Is vendor oversight documented in a way an inspector could follow?
-
Have we asked sites whether our processes are workable?
If any answer is uncertain, that is where to begin.
Testing your approach with peers
Guidance on paper only goes so far. Operations leaders learn the most when they hear how others have handled the same questions, including what did not work. That is the thinking behind the Evolution Summit, taking place on 19 to 20 January 2027 at the Four Seasons Hotel Westlake Village, California.
Modernizing clinical trial standards and models, including ICH E6(R3) implementation, is one of the program's key topics. The speaker line-up reflects the range of voices needed. Scott Gottlieb, MD, former Commissioner of the Food and Drug Administration, brings a regulatory perspective to the discussion. Senior operations leaders such as Jill Kearney, Vice President, Head of Clinical Trial Operations at Genmab, and Dalila Costa, Director, Global Clinical Development Operations at Gilead Sciences, offer the view from teams responsible for delivering studies. Namita Talwar of GSK moderates, keeping the conversation practical.
The invitation-only format matters here. In a closed-door setting, executives can compare notes on oversight models and partnerships without the pressure of a public stage.
Enquire Today - https://www.marcusevans.com/summit/evolution/jan27